Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/126289
Title: ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PROSTR study
Author: Podzamczer Palter, Daniel
Rozas, Nerea
Domingo, Pere (Domingo Pedrol)
Ocampo, Antonio
van den Eynde, Eva
Deig, Elisabeth
Vergara, Antonio
Knobel Freud, Hernando Javier
Pasquau, Juan
Antela, Antonio
Crespo, Manuel
Clotet, Bonaventura, 1953-
Muñoz, Jessica
Fernandez, Pedro
Geijo, Paloma
Rodríguez de Castro, Eduardo
Diz, Julio
Casado, Araceli
Torres, Covadonga
Keywords: Infeccions per VIH
Antiretrovirals
HIV infections
Antiretroviral agents
Issue Date: 1-Nov-2014
Publisher: Wiley
Abstract: Introduction: Tolerability and convenience are crucial aspects for the long-term success of combined antiretroviral therapy (cART). The aim of this study was to investigate the impact in routine clinical practice of switching to the single tablet regimen (STR) RPV/FTC/TDF in patients with intolerance to previous cART, in terms of patients’ well-being, assessed by several validated measures. Methods: Prospective, multicenter study. Adult HIV-infected patients with viral load under 1.000 copies/mL while receiving a stable ART for at least the last three months and switched to RPV/FTC/TDF due to intolerance of previous regimen, were included. Analyses were performed by ITT. Presence/magnitude of symptoms (ACTG-HIV Symptom Index), quality of life (EQ-5D, EUROQoL & MOS-HIV), adherence (SMAQ), preference of treatment and perceived ease of medication (ESTAR) through 48 weeks were performed. Results: Interim analysis of 125 patients with 16 weeks of follow up was performed. 100 (80%) were male, mean age 46 years. Mean CD4 at baseline was 629.59307.29 and 123 (98.4%) had viral load B50 copies/mL; 15% were HCV co-infected. Ninety two (73.6%) patients switched from a NNRTI (84.8% from EFV/FTC/TDF) and 33 (26.4%) from a PI/r. The most frequent reasons for switching were psychiatric disorders (51.2%), CNS adverse events (40.8%), gastrointestinal (19.2%) and metabolic disorders (19.2%). At the time of this analysis (week 16), four patients (3.2%) discontinued treatment: one due to adverse events, two virologic failures and one with no data. A total of 104 patients (83.2%) were virologically suppressed (B50 copies/mL). The average degree of discomfort in the ACTG-HIV Symptom Index significantly decreased from baseline (21915.55) to week 4 (10.89912.36) & week 16 (10.81912.62), pB0.001. In all the patients, quality of life tools showed a significant benefit in wellbeing of the patients (Table 1). Adherence to therapy significantly and progressively increased (SMAQ) from baseline (54.4%) to week 4 (68%), pB0.001 and to week 16 (72.0%), pB0.001. Conclusions: Switching to RPV/FTC/TDF from another ARV regimen due to toxicity, significantly improved the quality of life of HIV-infected patients, both in mental and physical components, and improved adherence to therapy while maintaining a good immune and virological response.
Note: Reproducció del document publicat a: https://doi.org/10.7448/IAS.17.4.19814
It is part of: Journal of the International AIDS Society, 2014, vol. 17, supl. 3
URI: http://hdl.handle.net/2445/126289
Related resource: https://doi.org/10.7448/IAS.17.4.19814
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PodzamczerD.pdf83.71 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons